PharmaShots | Incisive News in 3 Shots

Subscribe Now

selexipag

Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag- IV) to Treat Pulmonary Arterial Hypertension

Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag- IV) to Treat Pulmonary Arterial Hypertension

October 1, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us